Molbio Diagnostics IPO Subscription Status Day 1 – Live Updates & Key Details

Molbio Diagnostics opened its IPO for subscription on August 10, 2026. The company develops and manufactures diagnostic testing devices used to detect infectious and other diseases, with its flagship Truenat platform, a portable testing machine that delivers results in about an hour. As of March 31, 2026, its portfolio covered 30 diseases through 43 assays, including tests for tuberculosis, COVID-19, HIV, hepatitis B and C, and HPV. The company's TB test is among the rapid molecular diagnostic tests recommended by the World Health Organization for initial detection of TB and rifampicin resistance, and its Truenat technology holds patent protection in more than 100 countries.

This is a ₹939.70 crore IPO, made up of a ₹200 crore fresh issue and an offer for sale of ₹739.70 crore. The fresh issue proceeds are earmarked for capital expenditure toward setting up infrastructure for a research and development facility and Centre of Excellence, to be operated by wholly owned subsidiary Bigtec, among other purposes, while the OFS portion goes to existing shareholders selling part of their stake.

Price band is set at ₹768 to ₹807 per share. Lot size is 18 shares, so retail investors need ₹14,526 to apply at the upper end. The issue closes August 12, and listing is expected August 17 on both BSE and NSE.

Molbio Diagnostics IPO - Day 1 Subscription Status

Live Subscription Data (Update in Real Time): Category-wise Breakdown on Day 1

The issue opened to a slow start in the early hours before picking up pace as the day progressed.

Figures reflect readings through Day 1, August 10, 2026. A detailed category-wise breakdown (QIB, NII, retail) was still updating on trackers at the time of writing; check the NSE or BSE site directly for the most current split.

What Day 1 Numbers Indicate

The jump from 0.07x at 10:30 AM to 0.67x later in the day shows demand building up steadily through the trading session, a fairly typical pattern where early-morning bids are light and pick up meaningfully as the day goes on.

Ahead of opening, the issue secured a strong anchor book featuring marquee names like Goldman Sachs, BlackRock, and IFC (International Finance Corporation), alongside six mutual funds. That kind of institutional backing is a reasonable early signal of confidence in the business, even as public retail and NII bidding builds up more gradually on day one.

Brokerage coverage of the issue has also leaned largely toward "Subscribe" ratings, though with caveats flagged around customer concentration risk, worth keeping in mind alongside the strong anchor participation.

Day-wise IPO Subscription Trend

With a three-day bidding window, expect QIB and the remaining NII demand to strengthen further as the issue heads toward its August 12 close.

Molbio Diagnostics IPO - Allotment and Listing Date

Should You Apply for Molbio Diagnostics IPO?

A few things worth weighing before you decide:

• It's a mix of fresh issue and offer for sale, with the ₹200 crore fresh issue going toward R&D infrastructure and a Centre of Excellence under subsidiary Bigtec, while the larger ₹739.70 crore OFS portion goes to existing shareholders exiting part of their stake.
• FY26 revenue rose 42% year-on-year, though profit after tax grew a more modest 18%, suggesting some margin pressure even as the top line scaled up strongly.
• Molbio holds a distinctive position in India's diagnostics space, with WHO-recommended TB testing technology and patent protection across more than 100 countries, operating in a sector that's a cornerstone of India's expanding healthcare industry.
• The issue attracted a strong anchor book featuring Goldman Sachs, BlackRock, and IFC alongside six mutual funds, a meaningful signal of institutional confidence.
• Most broker coverage has leaned toward "Subscribe," though with caveats around customer concentration risk, worth weighing alongside the otherwise positive signals.
• Promoter holding will come down from 46.65% to 43.01% after the issue.

This is informational content, not investment advice. Weigh your own risk appetite before applying.

How to Apply for Molbio Diagnostics IPO

You can apply through any of these routes:

1. ASBA via net banking – log into your bank's net banking, go to the IPO section, select Molbio Diagnostics, enter quantity and bid price, then authorise.
2. UPI via broker app – open your broker app, find the IPO under current issues, enter your UPI ID and bid details, then approve the mandate on your UPI app.
3. Physical ASBA form – submit through your bank branch if you prefer the offline route.

Bid in multiples of the 18-share lot. Applying at the cut-off price improves your allotment chances since it matches the final discovered price.

Molbio Diagnostics IPO Important Dates

How to Check Molbio Diagnostics IPO Subscription Status

How to check Molbio Diagnostics IPO Subscription Status on NSE website

1. Go to the NSE India website and open the "Live IPO Bidding" section.
2. Select Molbio Diagnostics Limited from the dropdown.
3. You'll see category-wise bid numbers, updated through the trading day.

How to check Molbio Diagnostics IPO Subscription Status on BSE website

1. Visit the BSE India IPO page.
2. Search for Molbio Diagnostics under active issues.
3. Click on it to view live bid quantity against shares reserved, split by category.

How to check Molbio Diagnostics IPO Subscription Status on Ventura?

Log into your Ventura account, go to the IPO section, and select Molbio Diagnostics from the list of live issues. You'll find the live subscription numbers along with your own application status if you've already applied.

Conclusion

Molbio Diagnostics' IPO has picked up pace through Day 1, moving from 0.07x in the early morning to 0.67x as the day progressed. The company brings a distinctive position in India's diagnostics industry, with globally patented, WHO-recommended technology and a strong anchor book backed by names like Goldman Sachs, BlackRock, and IFC. With most brokerages leaning toward "Subscribe" and a three-day bidding window still ahead, this is one to track closely as demand builds toward the August 12 close.